Dr. Brian J. Moran, Awareness in Action and Sky High Referral Rates
“Today, over 85% of our [low-dose rate brachytherapy] patients are referred from former, satisfied patients,” says Moran. Because of this, Dr. Moran recognizes the value of brachytherapy in the community and the awareness in action. Former patients have even a monthly support group meeting that Dr. Moran and his Director of Research and Education attend.
Dr. Moran credits the baby boomer generation with this awareness in action. Whether it’s through social media or simply talking to a friend, patients are being introduced to brachytherapy through channels that weren’t available 10 years ago. Dr. Moran hopes to use these new channels to share patients’ stories and testimonials.
The more widely those stories are shared, the greater the opportunity for more men to take an active role in their treatment and reaching optimal quality of life thereafter.
That said, Dr. Moran notes that the internet is not always a reliable source and that he hopes to always provide patients with the most accurate and valuable information when making their treatment decision.
If you would like to learn more about how brachytherapy improves outcomes for many types of cancer patients, especially prostate cancer patients, contact info@isoray.com.
Initial Results From First Patient Dosed With Perspective Therapeutics’ Lead Drug VMT-α-NET Presented at The Treatment of Neuroendocrine Disorders at the 2023 PET/RTRC Annual Workshop Scientific Session
The result from first patient dosed with VMT-α-NET in India on a compassionate use basis showed favorable responses. The initial response was measured by a somatostatin imaging agent 68Ga-DOTANOC and demonstrated surprisingly favorable results after a single low dose...
Perspective Therapeutics (formerly known as Isoray, Inc.) Announces Financial Results for the Quarter ended December 31, 2022
Fiscal Calendar Year Changes from June to December Year End RICHLAND, WASHINGTON & CORALVILLE, IOWA – February 16, 2023 Perspective, Therapeutics Inc. (formerly known as Isoray, Inc.) (NYSE AMERICAN: ISR), a precision oncology company developing alpha-particle...
Isoray Inc. and Viewpoint Molecular Targeting Inc. Announce Name Change to Perspective Therapeutics Inc.
Company’s focus is on the advancement of cancer treatments using radiation, radiopharmaceuticals, and imaging technologies New corporate tagline and website introduced New ticker symbol to be NYSE American: CATX RICHLAND, WASHINGTON & CORALVILLE, IOWA – February...
